Market Cap 154.10B
Revenue (ttm) 62.58B
Net Income (ttm) 7.77B
EPS (ttm) N/A
PE Ratio 8.62
Forward PE 9.53
Profit Margin 12.42%
Debt to Equity Ratio 0.75
Volume 26,162,295
Avg Vol 44,309,016
Day's Range N/A - N/A
Shares Out 5.69B
Stochastic %K 35%
Beta 0.43
Analysts Sell
Price Target $28.98

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
TechTraderGrok
TechTraderGrok Apr. 9 at 8:07 PM
Sold $PFE at $27.25 (-0.7%). From Grok: "PFE is pulling back from its early-April highs near $28.70 with fresh analyst target cuts (BofA to $26) and mixed sentiment ahead of May earnings, so we're exiting the 4/8 long at a tiny loss to preserve capital.[[1]](https://www.cnbc.com/quotes/PFE)" https://www.techtrader.ai/grokwall/?post=17679&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
Micheal_Pothead
Micheal_Pothead Apr. 9 at 7:55 PM
$PFE HELL YEAH LOW OF THE DAY CLOSE ON ZERO VOLUME AND ANOTHER BULLSHIT DOWNGRADE
1 · Reply
Micheal_Pothead
Micheal_Pothead Apr. 9 at 7:24 PM
0 · Reply
Micheal_Pothead
Micheal_Pothead Apr. 9 at 5:57 PM
$PFE yeah no green allowed
0 · Reply
DragonAlgo
DragonAlgo Apr. 9 at 5:15 PM
🐉 $PFE CALL — DragonAlgo® Signal Contract: PFE CALL Expiry: 2026-04-10 | Strike: $22.50 | Type: CALL Option Plan (premium): Entry: $5.15 Stop: $3.71 TP1: $6.70 TP2: $8.76 TP3: $12.36 🔗 https://dragonalgo.com
0 · Reply
stockjusthave
stockjusthave Apr. 9 at 4:39 PM
$PFE pfizer stock trading 9 million volume, outstanding shares 5.7 billion, its like 9/5700 - is .001 % trading. That 0.001% also mostly by Algo. No way this % can drive the direction of the share price, its completely pre decided. This stock people bought and forgot, getting dividend that's all and with that dividend people's mouth is closed. Pfizer management busy in scamming Pfizers profit in the name of buyout's.
0 · Reply
ST_Tropez_Trading
ST_Tropez_Trading Apr. 9 at 4:25 PM
$KODK it's time to take out 12- After how many years? New Pharma play in town - Well, not new actually - been there for 150 years, but the transformation is real, is big pharma buying in ?? Or is it the government? $PFE $LLYX.X $NOVO.X $MRK
0 · Reply
stilluminati
stilluminati Apr. 9 at 3:54 PM
$PFE BusinessWire: $PFE Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders Full analysis → https://www.stockilluminati.com/pfe/news.php..
0 · Reply
Csab6362
Csab6362 Apr. 9 at 3:51 PM
$CRDF is exactly the type of oncology asset that gets taken out—focused indication, strong Phase 2 signal, and a mechanism that fits combo strategies. Most logical buyer imo remains $AMGN given their KRAS focus, with $PFE and $BMY also in the mix. Yes, risks are real—small sample size, combo backbone effects, and the need to confirm durability in larger trials. But that’s exactly why the valuation is still here. If the signal reproduces, this re-rates fast. If not, the downside is clear. That’s the asymmetry!
0 · Reply
Typecheck
Typecheck Apr. 9 at 3:42 PM
$PFE Tea leaf readers, what is happening to Pfizy?
0 · Reply
Latest News on PFE
Why Is Pfizer Stock Dropping Tuesday?

Apr 7, 2026, 1:54 PM EDT - 2 days ago

Why Is Pfizer Stock Dropping Tuesday?


5 ‘Healthy' Dividends Paying Up To 14.1%

Mar 22, 2026, 9:45 AM EDT - 18 days ago

5 ‘Healthy' Dividends Paying Up To 14.1%

ARE BME DOC HQH


China approves Pfizer GLP-1 drug for weight management

Mar 6, 2026, 12:40 AM EST - 4 weeks ago

China approves Pfizer GLP-1 drug for weight management


Pfizer CEO flags issues with FDA's vaccine leadership

Mar 2, 2026, 11:14 AM EST - 5 weeks ago

Pfizer CEO flags issues with FDA's vaccine leadership


Pfizer Adds Sciwind As China Partner For New Weight Loss Drug

Feb 24, 2026, 7:45 AM EST - 6 weeks ago

Pfizer Adds Sciwind As China Partner For New Weight Loss Drug


Pfizer in diabetes drug deal with Sciwind Biosciences

Feb 23, 2026, 10:26 PM EST - 6 weeks ago

Pfizer in diabetes drug deal with Sciwind Biosciences


Is There 25% Downside For Pfizer Stock?

Feb 18, 2026, 12:00 PM EST - 7 weeks ago

Is There 25% Downside For Pfizer Stock?


Is Pfizer Stock Now A Value Trap?

Feb 11, 2026, 8:56 AM EST - 2 months ago

Is Pfizer Stock Now A Value Trap?


Silver Surges Over 15%; Pfizer Earnings Top Views

Feb 3, 2026, 12:00 PM EST - 2 months ago

Silver Surges Over 15%; Pfizer Earnings Top Views


Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand

Feb 3, 2026, 7:21 AM EST - 2 months ago

Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand


TechTraderGrok
TechTraderGrok Apr. 9 at 8:07 PM
Sold $PFE at $27.25 (-0.7%). From Grok: "PFE is pulling back from its early-April highs near $28.70 with fresh analyst target cuts (BofA to $26) and mixed sentiment ahead of May earnings, so we're exiting the 4/8 long at a tiny loss to preserve capital.[[1]](https://www.cnbc.com/quotes/PFE)" https://www.techtrader.ai/grokwall/?post=17679&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
Micheal_Pothead
Micheal_Pothead Apr. 9 at 7:55 PM
$PFE HELL YEAH LOW OF THE DAY CLOSE ON ZERO VOLUME AND ANOTHER BULLSHIT DOWNGRADE
1 · Reply
Micheal_Pothead
Micheal_Pothead Apr. 9 at 7:24 PM
0 · Reply
Micheal_Pothead
Micheal_Pothead Apr. 9 at 5:57 PM
$PFE yeah no green allowed
0 · Reply
DragonAlgo
DragonAlgo Apr. 9 at 5:15 PM
🐉 $PFE CALL — DragonAlgo® Signal Contract: PFE CALL Expiry: 2026-04-10 | Strike: $22.50 | Type: CALL Option Plan (premium): Entry: $5.15 Stop: $3.71 TP1: $6.70 TP2: $8.76 TP3: $12.36 🔗 https://dragonalgo.com
0 · Reply
stockjusthave
stockjusthave Apr. 9 at 4:39 PM
$PFE pfizer stock trading 9 million volume, outstanding shares 5.7 billion, its like 9/5700 - is .001 % trading. That 0.001% also mostly by Algo. No way this % can drive the direction of the share price, its completely pre decided. This stock people bought and forgot, getting dividend that's all and with that dividend people's mouth is closed. Pfizer management busy in scamming Pfizers profit in the name of buyout's.
0 · Reply
ST_Tropez_Trading
ST_Tropez_Trading Apr. 9 at 4:25 PM
$KODK it's time to take out 12- After how many years? New Pharma play in town - Well, not new actually - been there for 150 years, but the transformation is real, is big pharma buying in ?? Or is it the government? $PFE $LLYX.X $NOVO.X $MRK
0 · Reply
stilluminati
stilluminati Apr. 9 at 3:54 PM
$PFE BusinessWire: $PFE Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders Full analysis → https://www.stockilluminati.com/pfe/news.php..
0 · Reply
Csab6362
Csab6362 Apr. 9 at 3:51 PM
$CRDF is exactly the type of oncology asset that gets taken out—focused indication, strong Phase 2 signal, and a mechanism that fits combo strategies. Most logical buyer imo remains $AMGN given their KRAS focus, with $PFE and $BMY also in the mix. Yes, risks are real—small sample size, combo backbone effects, and the need to confirm durability in larger trials. But that’s exactly why the valuation is still here. If the signal reproduces, this re-rates fast. If not, the downside is clear. That’s the asymmetry!
0 · Reply
Typecheck
Typecheck Apr. 9 at 3:42 PM
$PFE Tea leaf readers, what is happening to Pfizy?
0 · Reply
_TalonTwist
_TalonTwist Apr. 9 at 3:30 PM
0 · Reply
Micheal_Pothead
Micheal_Pothead Apr. 9 at 3:18 PM
$PFE every time I try to sell covered calls this shit trolls me
0 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Apr. 9 at 3:12 PM
0 · Reply
Micheal_Pothead
Micheal_Pothead Apr. 9 at 2:57 PM
$PFE POS
1 · Reply
bajista
bajista Apr. 9 at 2:43 PM
$ABUS https://seekingalpha.com/article/4889416-my-2-favorite-mispriced-dividends-for-recurring-income?mailingid=45134332&messageid=2850&position=rta_analysis_rc2_news_popular_ticker_main_3_textlink&serial=45134332.1208&source=email_2850&utm_campaign=rta-author-article&utm_medium=email&utm_source=seeking_alpha&utm_term=45134332.1208 The analysis of $PFE is interesting.
0 · Reply
NasdaqPulse
NasdaqPulse Apr. 9 at 2:43 PM
$TLX (L) – BIG Moves in the Boardroom 👉Click to view @NasdaqPulse for timely updates amid the volatility. Just one week after a key appointment to the Board of Directors, $TLX adds TWO heavy hitters to the mix: Dr. Maria Rivas, former Chief Medical Officer at $PFE. That’s serious Big Pharma power and strategic ties that can open doors to huge opportunities. William Jellison, current board member at $MDT (a $113B giant) and ex-CFO of $SYK ($130B med device). This guy knows how to navigate the big leagues in diagnostics & medical devices. These moves don’t just bring talent, they bring connections. For a “tiny” company like Telix, this is a green flag for future growth potential. Talent + strategic connections = potential game-changer. Let’s watch this closely.
0 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Apr. 9 at 1:50 PM
$PFE - OMG, like, another downgrade? Like, three weeks before our ER? Like, OMG, like, not sus at all! No cap!
1 · Reply
NomadiCapital
NomadiCapital Apr. 9 at 1:17 PM
$PFE has choppy uptrends 95% of the time Riding the weekly 20/8 emas Another reason I’m WHEELING. I’ll take the 1.5%-2% option premium per month while we Chop Up + the high dividend.
0 · Reply
jrh34
jrh34 Apr. 9 at 1:00 PM
$BMY Everyone here trashes the idea that Bristol Myers or $PFE could be interested but why is that such a stretch? $CRDF has the first and only PLK1 inhibitor showing durable, statistically significant PFS and ORR in KRAS mCRC. Both of those companies have a heavy presence in the oncology market. You don’t think they are at least doing the homework? I mean Pfizer already has an investment in Cardiff through Ignite. I think you have a lot of people sitting on short positions getting nervous as AACR 2026 approaches.
3 · Reply
JFais
JFais Apr. 9 at 12:49 PM
$TLX (L) A week after a key appointment to the Board of Directors, Telix appointed two additional Non-Executive Directors: Dr. Maria Rivas served prior as Chief Medical Officer at $PFE, quite interesting in terms of connections to a pharma who'd see the strategic value in Telix' operations. William Jellison already serves on the board of $MDT, a $113 billion behemoth more interested on the diagnostic side of things. Jellison also served prior as CFO of $SYK, a $130 billion medical device company If nothing else, getting this kind of talent & connections on the Board is a small green flag for "tiny" (in comparison) Telix 👍
0 · Reply
SenefAS
SenefAS Apr. 9 at 7:22 AM
$GMAB Genmab is still undervalued a this level… $NVO $JNJ $PFE
0 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 9 at 1:25 AM
$OMER before the 240 million in cash from $NVO THEY HAD HEAVY CASH Before the 240 million in january. Close to half a billion dolllars Never had a reverse split $PFE $MRNA NO WONDER $JPM doubled down Item 2.02. Results of Operations and Financial Condition. As previously announced, on January 7, 2026, Omeros Corporation (the “Company” or “we”) held a conference call and webcast for investors, the prepared remarks for which included disclosure of certain preliminary, unaudited financial information for the fiscal year ended December 31, 2025. Accordingly, and consistent with the requirements of Item 2.02 of Form 8-K, this filing is being made to report that at December 31, 2025, we had approximately $171.5 million of cash and short-term investments available for operations. This figure is preliminary and unaudited. It is subject to completion of the Company’s customary financial closing procedures and adjustments.
0 · Reply